Skip to main content
Fig. 18 | Cancer Nanotechnology

Fig. 18

From: Evaluation of the anticancer potential of CD44 targeted vincristine nanoformulation in prostate cancer xenograft model: a multi-dynamic approach for advanced pharmacokinetic evaluation

Fig. 18

Histopathology of the VC treatment group showed very significant neuro (C3), significant hepatic (C1) and renal (C4) and less significant cardio (C2) and lung toxicity(C5) compared to NFs of VC-loaded TCs-HA treatment group with lesser off-target toxicities (D1 to D5) and prominent cytotoxic effect at the tumour site with less angiogenesis and invasion (D6)

Back to article page

Cancer Nanotechnology

ISSN: 1868-6966

Contact us